RecruitingPHASE2, PHASE3NCT05691478
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Studying Bone sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Michael W BishopChildren's Oncology Group
- Intervention
- Bone Scan(procedure)
- Enrollment
- 1122 target
- Eligibility
- 40 years · All sexes
- Timeline
- 2023 – 2030
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Banner Children's at Desert, Mesa, Arizona, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Mattel Children's Hospital UCLA, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05691478 on ClinicalTrials.govOther trials for Bone sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07479732Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic OsteosarcomaPeking University People's Hospital
- RECRUITINGPHASE1NCT07222735Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory SarcomasSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07359053MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced SarcomaShanghai 6th People's Hospital
- RECRUITINGPHASE2NCT06939855QL1706 in the Treatment of Advanced Bone and Soft Tissue SarcomaSun Yat-sen University
- RECRUITINGNCT07215611Financial Toxicity in Patients With Resected Soft Tissue and Bone SarcomasM.D. Anderson Cancer Center
- RECRUITINGNCT06958107LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma PatientsWake Forest University Health Sciences
- RECRUITINGPHASE1, PHASE2NCT07066982Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced SarcomasEssen Biotech
- RECRUITINGNANCT06796543Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone SarcomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins